Merck & Co. lost its $200 million jury verdict over Gilead Sciences Monday for its own misconduct in the dispute over a wildly successful Hepatitis

Opening the Courtroom Door
Merck & Co. lost its $200 million jury verdict over Gilead Sciences Monday for its own misconduct in the dispute over a wildly successful Hepatitis
In a partial victory for Merck & Co., a federal judge held Monday Gilead Sciences’ blockbuster hepatitis C-fighting drugs Sovaldi and Harvoni violate Merck patents,